CBA China First Annual Conference in 2024

The Chinese Biopharmaceutical Association (CBA) China First Annual Conference is scheduled to convene on Sunday，June 28, 2024,  at Suzhou International Expo Center (Hall A, C-E). The conference will be held both in-person and online simultaneously.

Introduce of CBA

Chinese Biopharmaceutical Association-USA (CBA) was established in 1995. It is the largest Chinese-American professional association in the USA. The primary purpose of CBA is to serve as a bridge to facilitate comprehensive communications and collaboration  in the biopharmaceutical fields between the USA and China, and to provide a good environment for the development and cooperation of biopharmaceutical companies and scientific research institutions.

CBA is headquartered in Maryland and has branches in Boston, Philadelphia, and Canada. It currently has more than 10,000 individual members and over 1,000 corporate members. The members of CBA come from diverse sources, including emerging technology companies in the USA and China, multinational pharmaceutical companies, colleges and universities, scientific research institutions, government regulatory agencies such as the FDA,  various research and industrial development support funds, legal and intellectual property firms, and other professional organizations. More than 80% of CBA’s individual members have a doctoral degree. With CBA’s increasing contributions to biopharmaceuticals, more and more members have made significant achievements in scientific research and economic development in both China and the USA. Many senior American scientists, successful entrepreneurs, and bioinvestors have become members of CBA. CBA has a good reputation internationally, with members all over the world, including China, the USA, Europe, Canada, Australia, Singapore and Japan.

Over the past 28 years, CBA has consistently adhered to its mission of promoting communications and collaboration among biopharmaceutical professionals. It is also committed to advancing the life sciences and health industries fostering business cooperation and partnerships between different countries and regions, especially between China and the USA. CBA has become an incubator for talents and entrepreneurs, cultivating an environment for collaborative growth and innovation among biopharmaceutical companies and research institutions. CBA has hosted or co-organized special workshops, seminars, annual meetings, and social activities annually with other organizations. It has become a platform that allows professionals to share knowledge and in-depth learning, lead industry development, build connections, and pursue career development. CBA has grown through the dedication of its members and the continuous support of partners and sponsors, year after year.

CBA is actively promoting the exchange of biopharmaceutical talents and collaborative projects between China and the USA, while also focusing on developing and commercializing innovative pharmaceutical products. The scope includes vaccines, new anti-tumor drugs and antibodies, nucleic acid drugs, human longevity and health, microbial molecular diagnosis, gene therapy, artificial intelligence and precision medicine, modern biopharmaceutical manufacturing, laws, and regulatory regulations, investment funds for various research and industrial development projects. CBA aims to meet the global clinical needs for the treatment of various diseases,  striving to serve patients in multiple ways and benefit mankind. Within the fields of innovation and entrepreneurship, many outstanding and hard-working entrepreneurs and investors have emerged from the presidents and members of CBA, achieving remarkable results. At the same time, they have made a positive contribution to scientific and technological exchanges, especially in biopharmaceuticals. In the future, the global biopharmaceutical and healthcare industries will continue to face many challenges and opportunities. CBA is committed to forging ahead, actively preparing to meet these new opportunities and challenges!

TBD“Gather talents through competition, strengthen production through competition, and develop the industry through competition.” Connect multiple domestic and international investment institutions to activate the atmosphere of biopharmaceutical entrepreneurship and investment. Promote industrial innovation, development, and ecosystem construction, creating efficient combination of enterprises and capital. Effectively transform and accelerate the implementation of high-quality biopharmaceutical projects, build a communication and interaction platform for these projects and investment institutions, and help entrepreneurs and companies grow rapidly. 

1. The Title of the conference

The first Annual Conference of Chinese Biopharmaceutical Association-USA 2024 in China

2. Time arrangement

Pre-conference meeting: afternoon of June 27, 2024

Conference: June 28-29, 2024

3. Conference location Suzhou International Expo Center (Hall A, Hall C, Hall D, Hall E) 

4. Scale of the Conference 20,000+ participants 

5. Organizational structure

Sponsor: Chinese Biopharmaceutical Association (CBA-China)

Co-organizers: National Biopharmaceutical Technology Innovation Center, Science and Technology Investment Center of Suzhou Industrial Park, BioBAY

Organizer: Suzhou Yuncheng Wanchuan

Support unit: TBD 

6. Event at the conference

Pre-conference meetings, reports, unveiling ceremonies, corporate product launches, entrepreneurial project roadshow competitions, corporate/cultural/cultural tourism exhibitions, cooperation project signings, talent settlement & corporate talent strategy, exchanges between Chinese and foreign institutions, business cooperation and exchanges, Jinji Lake Night – Cocktail parties, alumni associations, school alliances, corporate visits, etc. 

6.1 Pre-meeting

In seminar format, participants will include government representatives, experts from various forums, business representatives, international guests, regulatory agencies, financial institutions, advanced research institutions, hospitals, etc. 

6.2 Report speech

1,000+ guests from China and abroad were invited to attend,  including several Nobel Prize winners, as well as domestic and international academicians, experts, and scholars. Participants also include FDA medical review experts, representatives of outstanding entrepreneurs, regulatory agencies, advanced research institutions, clinical hospitals, and investment and financing institutions. The aim is to inject new vitality and power into the development of the pharmaceutical field, promote innovation and progress, and thereby contribute to the development of the industry. 

6.3 unveiling ceremony

Witness the unveiling of the CBA Suzhou branch at the opening ceremony of the conference.

6.4 Enterprise product launch conference

Demonstrations of new corporate products, research results, and outstanding entrepreneurial projects will be on display. Companies will showcase their latest achievements and R&D products at the conference to gain more attention. 

6.5 Entrepreneurship Project Roadshow Competition

“Gather talents through competition, strengthen production through competition, and develop industry through competition”, connect multiple domestic and foreign investment institutions, activate the atmosphere of Biopharmaceutical entrepreneurship and investment, promote industrial innovation and development and ecosystem construction, and open up the efficient combination of enterprises and capital. Effectively transform and accelerate the implementation of high-quality Biopharmaceutical project results, build a communication and interaction platform for high-quality projects and investment institutions, and help entrepreneurs and companies grow rapidly. 

6.6 Corporate/cultural/cultural tourism exhibitions

6.6.1 Corporate exhibition

Exhibitions of corporate products, corporate business, corporate services and peripherals. CRO/CDMO/testing service companies, laboratory consumables companies, reagent materials, services, equipment and other companies receive good exhibition opportunities 

6.6.2 Suzhou characteristic cultural exhibition

Covers many Suzhou-specific cultural treasures such as Kunqu Opera, Pingtan, Song Brocade, Kesi, and Wumen calligraphy and painting, which display Suzhou’s rich and profound cultural charm in a multi-dimensional and all-round way. It will effectively promote the spread of local culture and let more people Appreciate the unique charm of Suzhou. 

6.6.3 Suzhou cultural tourism exhibition

Set up Thematic sections such as Suzhou Garden Tour and Ten Scenes of the Canal. Present Suzhou’s high-quality cultural and tourism resources, its intangible cultural heritage, and diverse Su-style lifestyles to domestic and foreign guests through interactive experiences, prize-winning Q&A and other activities. This initiative aims to attract more people to visit Suzhou and stimulate cultural tourism consumption. 

6.7 Signing of cooperation projects

Utilize the advantages of the conference platform to efficiently integrate resources and promote the park’s favorable policies and excellent business environment to high-quality enterprises. This aims to support the park’s investment promotion efforts and facilitate the implementation of high-quality projects.

6.8 Talent implementation & corporate talent strategy

6.8.1 Talent implementation

The park prioritizes people and leads the country in attracting and supporting top talents. The combined advantages of policy support, scientific research investment, and industrial improvement have attracted talents such as top students from prestigious research institutions, returnees, and corporate executives to settle here, thereby providing more powerful intellectual support for technological innovation in the park.

6.8.2 Corporate talent strategy

Gather high-precision talents from China and abroad, build a platform for enterprise and talent exchange, facilitate face-to-face communication, recruit outstanding talents for enterprises, bridge the talent gap of enterprises, and support innovation and development.

6.9 Exchanges between Chinese and foreign institutions

Attract teams from Chinese and foreign universities to participate in the conference, expand Suzhou’s “circle of friends” for international educational exchanges, promote personnel exchanges and deep cooperation in the field of education between both sides, cultivate more globally-oriented talents, and help establish a new flagship for Suzhou’s education in the global arena.

6.10 Business cooperation and exchanges

Facilitate Face-to-face communication between the upstream and downstream sectors of the industrial chain, engage in direct dialogue with corporate executives, and foster close interactions to promote greater cooperation. (Note: The conference includes corporate representative gatherings, business dinners, corporate receptions, and numerous networking opportunities.)

 6.11 Jinji Lake Night-Cocktail Party (Time: June 28, 18:00-21:30)

An entrepreneur exchange reception will be held at the Moonlight Dock beside the Jinji Lake,  featuring cultural market , Music, beautiful scenery, and night markets, creating a relaxed and pleasant atmosphere for communication. Wine will be served as a medium to exchange ideas, broaden horizons, and discuss development together. 

6.12 Alumni Association

Michigan Alumni Association, Cambridge University Alumni Association, Peking University Alumni Association, Tsinghua Alumni Association, Fudan Alumni Association, China Pharmaceutical University Alumni Association, Shenyang Pharmaceutical University Alumni Association, Zhongshan University Alumni Association , etc. 

6.13 College Alliance

College alliance signing ceremony. 

6.14 Company visits

Returnees, corporate executives, and high-precision talents are invited to visit the biopharmaceutical companies in the park. 

7. Organizing Committee

organizing Committee:

Dajun Yang (first president of CBA-China Branch),Guoliang Yu,Yang Lu,Shoubai Chao,Song Wu, Jingyu Luan,You Li, Chunlin Chen, Lei Fu, Weiwu he, Yifan Zhai, Ziping Wei, Yingxian Xiao, Yuqi Zhao, Li Li, yuxin men, Qi Zeng, Hongjun Yang, Xuyang song, Zhao Wang, Ling Yang, Qing Liang, Jingke Weng, Yali Li, Hang Lu, Hao Cai, Qing Li, chuanhua Xing, Lin Sun, Dan Zhang, Chunhong Liu, Dewan Zeng, Yuling Li, Min Zhu, mengqi fan, Yuanjun Sun, ruyi he, Yaping Wang, Chao Liu, Lin Li, Ting Deng, Jiming Cai, Yumin Zhang, Peng Wang, Tong Guo, Ke Ding,  Liying Sun, Gengcheng Yang, Hui Feng Dadong Chen, Xiangyang Zhu, Gang Chen, Fei You, Yixing Han, Haomeng Wang, Jinbo Gou, Changlin Tian, Leping Li, Jianfeng Xu, Jianyuan Tang, Xiang Li,Weijun Sha, Xinle Wu, Zhaojun Mo, Jianguang Li, Zhen Huang, Jinsong Guo, Shiqiao Zhu, Mingjiu Chen, Xun Liu,Yiping Rong, Peikun Zhao, Jinna Cai, Wenjie Li, Jianxiong Chu.

Advisory Committee: TBD

8. Agenda of the conference

Main venue: life and health

Session 1/2: Small molecule field

Topic 1: New Technology for Drug Screening and the Practice of New Targets (Planner/Moderator: Weijun Sha)

Topic 2: “Development of Non-Targeted Drugs and New Technology” (Planner/Moderator: Leping Li)

Topic 3: Targeted Protein Degradation Technology: PROTAC and Molecular Glue Technology (Planner/Moderator: Ke Ding)

Topic 4: “International and Domestic Perspectives: Opportunities and Challenges in the Research and Development of Small Molecule Drugs” (Planner/Moderator: Yuanjun Sun)

Topic 5: “Globalization Perspective: The Road of Innovative Small Molecules Drugs Going Abroad” (Planner/Moderator: Tong Guo)

Topic 6: Differentiated Layout of New Non-tumor Drugs (Planner/Moderator: Jinsong Guo)

Session 3/4: Macromolecule Field

Topic 1: Discussion on the Development and Commercialization of Antibody and Protein Drugs (Planner/Moderator: Shiqiao Zhu)

Topic 2: The New Trend of Combination Therapy for Immunotherapy (Planner/Moderator: Qi Zeng）

Topic 3: Platform of Emerging Antibody Discovery Technologies (Planner/Moderator: Hui Feng/Xiangyang Zhu)

Topic 4: Development of Bispecific and Multispecific Antibodies (Planner/Moderator: Xuyang Song)

Topic 5: New Targets and the Development of the World’s First Antibody Drugs. (Planner/Moderator: Mingjiu Chen)

Topic 6: Selection and Development of Nanobodies.  (Planner/Moderator: Xun Liu)

Session 5/6: ADC field (Ziping Wei,Qing Li)

Topic 1: Innovation and Exploration of ADC Technology (Forum title: ChemExpress, TOT BIOPHARM) (planner/moderator: Qing Li)

Topic 2: Clinical Research and Challenges of ADC (planner/moderator:  Yixing Han)

Topic 3: ADC Coupling and Small Molecular Platform Innovation (Planner/Moderator: Fei You)

Topic 4: ADC’s Way to abroad and international cooperation(co-sponsored by ChemPartner)  (Planner/Moderator: Ziping Wei)

Topic 5: ADC Process Development and CMC (Planner/Moderator: Gengcheng Yang)

 Topic 6: ADC Translational Medicine Research and Biomarkers Exploration (Planner/Moderator: Chunhong Liu)

Session 7/8: Advanced Treatment Field (Yuling Li, Min Zhu)

Topic 1: “CXO Helps the Research and Commercialization of Advanced Therapeutic Drugs” (Planner/Moderator: Yuling Li)

Topic 2: Progress and Prospect of Next-Generation Cell Therapy (Planner/Moderator: Min Zhu)

Topic 3: Progress and Prospect of Next-Generation Cell Therapy (Planner/Moderator: Min Zhu) 

Topic 4: Frontier Therapies (Moderator: Guoying Zhou )

Topic 5: Research on Gene Therapy Vectors and Gene Editing (Planner/Moderator: Yuling Li)

Topic 6:Gene Therapy Vector Research and Gene Editing (Planner/Moderator: Yuling Li) 

Session 9: AI and new technologies (joint planning by DP Technology)

Topic 1: “The new Paradigm of AI and New Technology Empowering Biopharmaceutical research and development” (Planner/Moderator: Mengqi Fan)

Topic 2: Exploration and Promotion of AI Technology and Digital Health in Clinical Applications, Drug Research, and Life Sciences (Planner/Moderator: Xuyang Song)

Topic 3: “AI and New Technology Empowering New Targets, New Mechanisms, and Frontier Biology Research” (Planner/Moderator: Mengqi Fan/Bingfeng Li)

Session 10/11: Vaccine field (Shoubai Chao, hang Lu)

Topic 1: The Development and Challenges of Innovative Vaccines (Planner/Moderator: Shoubai Chao)

Topic 2: Quality Management of Innovative Vaccines (Planner/Moderator: Zhaojun Mo)

Topic 3: New Vaccine Adjuvant and Carrier Technology (Planner/Moderator: Jianguang Li)

Topic 4: mRNA Vaccine and Drug Development (Planner/Moderator: Haomeng Wang)

Topic 5: “Innovative Development of Therapeutic Vaccines and Key Regulatory Points” (Planner/Moderator: Hang Lu)

Topic 6: Discussion on the Internationalization of Vaccines in China (Planner/Moderator: Jinbo Gou)

Session 12/13: Clinical field (Yuxin Men)

Topic 1: Interpretation of Policies and Regulations Related to Clinical Trials in China and the USA (Planner/Moderator: Yuxin Men)

Topic 2: Clinical Experiment in the Context of Artificial Intelligence and Digital Transformation I (Planner/Moderator: Ruyi He)

Topic 3: Clinical Experiment II in the Context of Artificial Intelligence and Digital Transformation II (Planner/Moderator: Chao Liu)

Topic 4: Application of Real-World Data in Clinical Research (Planner/Moderator: Yaping Wang)

Topic 5: Challenges and Innovations in Clinical Operations (Planner/Moderator: Liying Sun)

Topic 6: Opportunities and Challenges in Innovative Clinical Trial Design (Planner/Moderator: Gang Chen)

Session 14: Investment and BD (Dewan Zeng)

Topic 1: ” Development of enterprise with the help of Investment and Merger” (Planner/Moderator: Dadong Chen)

Topic 2: Business Development and Cross-Border Trading of Innovative Drugs (Planner/Moderator: Dewan Zeng)

Topic 3: Investment Landscape and Capital Structure of Pharmaceutical Innovation (Planner/Moderator: Dewan Zeng)

Session 15: Global Registration Declaration and Regulations (Li Li, Zhao Wang)

Topic 1: Strategy and Practice of Clinical Declaration for New Drugs in China and the USA (IND/CTA) (Planner/Moderator: Zhao Wang, Lin Li)

Topic 2: Strategic Planning of Dynamic Changes in Global Regulatory Supervision (Planner/Moderator: Dan Zhang, Li Li)

Topic 3: Strategy and Practice of China-US New Drug Listing Declaration (NDA/BLA) (Planner/Moderator: Li Li, Ting Deng)

Session 16: Polypeptide Forum

Topic 1: Development and Delivery System of Polypeptide Drugs (Planner/Moderator: Changlin Tian)

Topic 2: Process Development and Quality Research of Polypeptide Drugs (Planner/Moderator: Hong Li)

Topic 3: Commercial Production of Polypeptide Drugs (co-sponsored: Biochemistry of middle peptide)(Planner/Moderator: Xiang Li)

Session 17: Nucleic Acid Forum (co-sponsored by Medicilon Chunlin Chen)

Topic 1: Frontier Research on Nucleic Acid Drug Innovation (Planner/Moderator: Jinna Cai)

 Topic 2: Technological Development of Nucleic Acid Drugs (Planner/Moderator: Wenjie Li)

Topic 3: Industrialization Innovation of Nucleic Acid Drugs (Planner/Moderator: Jinna Cai)

Session 18: Nuclide Drugs Forum (Qing Liang)

Topic 1: Research and Development of Nuclide Drugs _R&D (Planner/Moderator: Yumin Zhang)

Topic 2: Production and Supply of Nuclides and Nuclide Drugs, CMC (Planner/Moderator: Jiming Cai)

Topic 3: Considerations of Clinical Design for Late Development of Nuclide Drugs (Planner/Moderator: Qing Liang)

Session 19: Future development direction of diet Drugs

Topic 1: Translational Medicine/Scientific Consideration of Diet Drugs (Planner/Moderator:  Jianfeng Xu)

Topic 2: New Targets and New Molecular Design (Planner/Moderator: Zhao Wang/Xinle Wu)

Topic 3: Clinical application of weight-loss drugs (Planner/Moderator: Tong Guo)

Session 20: Forum of Bottom Innovation for Nucleic Acid and the 11th International Conference of Drug Innovation on Nucleic Acid and protein Structural in Chemistry and Biology (planner/moderator: Zhen Huang)

Topic 1: A New Paradigm of biopharmaceutical research and development Empowered by bottom Innovation of Nucleic Acid (Planner/Moderator: Huang Zhen)

Topic 2: The Bottom Discovery and Innovation Drive of Nucleic Acid-Protein Targets and Drug Structure (Moderator: Demin Zhou /Haitao Li)

Topic 3: The Bottom Discovery and Delivery Innovation of Nucleic Acid-protein Vaccines and Other Nucleic Acid Drugs (Moderator: Haitao Li /David Lilley)

Session 21

Topic 1: The promotion of biopharmaceuticals from Policy and Law (Planner/Moderator: Lin Sun /Yin Wang)

Topic 2 (morning): High-quality development of traditional Chinese medicine (curator: Jianyuan Tang)

Topic 2 (afternoon): Inheritance and Innovation of Traditional Chinese Medicine (Planner/Moderator: Jingke Weng /Haiying Xu)

Session 22 precision medicine

Topic 1: AI Precision Medicine and biopharmaceutical (Planner/Moderator: Chuanhua Xing)

Topic 2 (morning): Translational Medicine/Precision Medicine (Planner/Moderator: Yali Li)

Topic 2 (afternoon): Translational Medicine/Precision Medicine (Planner/Moderator: Hongjun Yang)

Session 23

Topic 1: Special Session of Philadelphia

Topic 2: CNS (Planner/Moderator: Peng Wang)

Topic 3: Special Session of Shenyang Pharmaceutical University Alumni Association

Session 24:

Topic1：Special Session of Fudan University Alumni Association

Topic2：Medical Devices (Planner/Moderator: Chu Jianxiong)

Session 25：

Topic1：Special Session of Zhongshan University Alumni Association

Topic2：CBIITA consortium symposium

Session 26：Pharmacopoeia Committee training meeting

Session 27：Conclave (Planner：New Drug Founders）

Session 28：The First Global Chinese Biopharmaceutical Entrepreneurship Competition of CBA (co-sponsored by CBA, Yuanhe Holdings, BioBAY and Shenghe Innovation Center, You Li)

Sponsors and Partners